Drug
Mexiletine
Mexiletine: highest development phase Approved, developed by Lupin, Teva. 4 trial records tracked on RxWires.
- Highest phase
- Approved
- Developer
- Lupin, Teva
Trials
| Drug | Phase | Indication |
|---|---|---|
| MEXILETINE HYDROCHLORIDE | Approved | |
| Mexiletine 167 mg NCT04700046 | Phase 3 | Myotonic Dystrophy Type 1 and Type 2 |
| Mexiletine NCT04624750 | Phase 3 | Myotonic Dystrophy |
| Mexiletine NCT04622553 | Not Applicable | Myotonic Disorders |
Latest
No recent events.
Follow Mexiletine on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.